Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

FDA approves ViiV's two-drug HIV regimen

Sandi Wong, Staff Writer
April 12, 2019 6:55 PM UTC

FDA approved Viiv's Dovato dolutegravir/lamivudine for HIV-1 infection in treatment-naïve adults. The product is a once-daily, single-tablet regimen of dolutegravir and lamivudine that the company plans to launch in 2-3 weeks at a wholesale acquisition cost (WAC) of $2,295 per month.

Gilead Sciences Inc. (NASDAQ:GILD) markets three-drug regimen Biktarvy bictegravir/emtricitabine/tenofovir alafenamide to treat HIV-1 infection. Biktarvy's WAC for a 30-day supply of the drug is $3,090...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Viiv Healthcare Ltd.